C
Staff of Corporate and Venture
Development (CVD)
|
Robert
L. Taber, Ph.D., Vice Chancellor for Corporate and Venture Development at Duke University Medical
Center and Health System, heads the Offices of Technology Licensing and Venture
Development, and Corporate Research Collaborations.
The former Office is responsible for patents and licenses and new
venture activity for the University as a whole, and the latter for commercially sponsored
research, corporate gifts, and selected corporate vending relationships for the Duke
School of Medicine and the Health System in particular.
Dr. Taber obtained his B.A. from
Harpur College, S.U.N.Y. in 1964, his Ph.D. from the University of Pittsburgh School of
Medicine in 1969 and went on to a post-doctoral fellowship at MIT with Dr. David
Baltimore. He then joined the Microbiology faculty of the University of Massachusetts
School of Medicine at its formation, as an Assistant Professor (1971-1973). In 1973 he moved to Roswell Park Memorial Institute
as a Senior Cancer Research Scientist (tenured) while holding an adjunct appointment in
Microbiology at the State University of New York at Buffalo.
In 1979 he left to become Associate Director of the Northern California
Cancer Program (the National Cancer Institute Bay Area Cancer Center) based at Stanford
and had an adjunct appointment and laboratory in the Department of Pharmacology at the
University of California School of Medicine, San Francisco.
Dr. Taber left academics in 1981
to participate in the founding of Integrated Genetics, Inc. in Framingham MA as Vice
President, Corporate Development. The company
was based on DNA technology for both diagnostic and therapeutic applications and went
through two private venture and two public rounds of financing by 1985. The company was subsequently acquired by Genzyme.
In 1985, Taber was recruited to
become President and CEO of EG&G MRI, based in Worcester, MA, a division of EG&G,
Inc. (now PerkinElmer, Inc.), EG&G at the time was an instrument and government
services company with ~$3B in sales. His division performed biomedical testing for the
biotechnology industry, NIH and the military. During
Tabers tenure with the company, the division he led doubled in sales to about
$20,000,000 with 220 employees while maintaining consistent profitability. The division
was subsequently acquired by Charles River Laboratories. During that time as President of
EG&G MRI he also maintained an office at corporate headquarters and worked with both
(1) EG&G Ventures, an internal fund for strategic start-up investment and (2)
Corporate Business Development where he participated in initiatives that subsequently
generated billions of government revenue to the Corporation.
In 1990, Dr. Taber left EG&G
to be a founder, as President and CEO of One Cell Systems, an analytic device company
based on MIT technology for cellular analysis and separation. The company is still in business in Cambridge, MA.
In late 1992, he was recruited to
Duke University Medical Center as an Associate Vice Chancellor to assume responsibility
for patent and licensing activities for the whole University. Over the course of the next few years he acquired
additional responsibility for new venture development, selected international initiatives,
commercial agreements and selected vending relationships.
He was promoted to a Vice Chancellor level position in 1998.
|
 |
Robert L.
Taber, Ph.D.
919-684-3628
taber002@mc.duke.edu
|
|
| Rose Ritts, PhD,
is the Executive Director of Dukes Office of Licensing & Ventures. With a
demonstrated track record of new product and business development in biotechnology,
medical devices, and high-tech markets across startup, corporate and government
environments, Dr. Ritts oversees the licensing and ventures operations of Duke University
and Duke Medical Center with an emphasis on a proactive approach to licensing, new company
formation and technology development. Her experience includes designing implantable
devices; serving as a program manager for biowarfare defense systems at DoD's Defense
Advanced Research Projects Agency; managing a biotechnology and materials business unit
within a large New Jersey corporation; performing IP and technical due diligence as a
consultant to venture capital firms; and most recently as founder and CEO of a
venture-capital-funded biotech startup, PowerZyme Inc, in Princeton, New Jersey. Ritts
received her BS in biomedical engineering from Duke, her MS and PhD from Stanford in
electrical engineering, and graduated from Stanford's Entrepreneurial Executive Management
Program. |
 |
Rose Ritts, PhD
Executive Director
919-681-6412
urose.ritts@duke.edu
www.olv.duke.edu

|
|
| Dr. Smith holds
responsibility for all of the Duke Medical School's research-related interactions with
commercial entities including clinical trials, non-clinical sponsored research, material
transfers, and other related endeavors. Dr. Smith also has intellectual property
management responsibilities, particularly in the context of that arising from, or closely
associated with, commercially sponsored research projects.
Prior to joining Duke in 1994, Dr. Smith had spent over
twelve years in various corporate R&D; research and management positions, including in
the TSI Corporation R&D; Division, the EG&G; Mason Research Institute, and at GTE
Laboratories. His military service was as an Army intelligence officer stationed at the
U.S. Army Foreign Science and Technology Center.
Dr. Smith received his Ph.D. in biochemistry from the
University of Virginia. He also holds an M.S. in organic chemistry from Northwestern
University, and a B.S. in chemistry from Washington and Lee University. His postdoctoral
experience includes research at the Institute for Neurobiology in Jülich, Germany, the
Department of Physiology at Washington University, and the Marine Biological Laboratory,
Woods Hole. Dr. Smith holds four patents and is the author of numerous scientific
publications. He is a member of Phi Beta Kappa and Sigma Xi. |
 |
H. Gilbert Smith, Ph.D.
919-681-6497
smith087@mc.duke.edu
|
|
| Mr. Herosian holds a BA
in Economics and a BS in Biology from Tufts University, as well as an MBA from Rutgers.
Prior to joining Duke, he was the founder of a successful Research Triangle Park based
technology company. While leading the company, Alan successfully secured venture capital
financing totaling $10 million, effectively obtained and linked proprietary technologies
via acquisition and licensing agreements and positioned the company for its successful
Initial Public Offering. Mr. Herosian is also a veteran of the biotechnology industry,
having held various executive positions with two major pharmaceutical companies. As
Director, Corporate Alliances & Development, he is actively involved in many facets of
corporate partnering and business development at Duke University Medical Center and
throughout the Duke Health System. |
 |
Alan Herosian, M.B.A.
919-419-4636
heros001@mc.duke.edu
|
|
| Mr. Freck holds an MBA
from the Fuqua School of Business at Duke University and an AB in history from Princeton
University. His career in health care began in 1992 with the SunHealth Corporation where
he analyzed and managed network development and contract negotiation projects for partner
hospitals. In 1994, he came to the Duke University Medical Center to join the Network
Services and Contracting division, focusing on managed care contract business development
and negotiations. In his seven years in managed care at DUMC, he developed Duke's
portfolio of specialty network contracts, pharmacy benefit management contracts, and
managed special case price negotiations for cardiovascular and transplant services. In
April 2001, he joined OST as an Associate Director in Corporate Programs. |
 |
Dean A. Freck, M.B.A
919-419-5031
freck001@mc.duke.edu |
|
| Mitch
Dozier, MBA, is the Director of Operations & Finance for Corporate & Venture
Development and the Office of Licensing & Ventures. Previously, he worked as a
management consultant with Andersen Consulting and Premier and as an internal consultant
with Duke University Health System. In a variety of organizations, he has led efforts in
process design, quality improvement, strategic planning, new product development, software
development, marketing, decision support, balanced scorecards, budget management, cost
accounting and customer service. Dozier received his MBA from the Fuqua School of Business
at Duke University and a BS in Business (Finance) from the University of North Carolina,
Chapel Hill. |
 |
Mitch Dozier, MBA
Business Manager 919-681-7591
mitch.dozier@duke.edu
|
|